152 related articles for article (PubMed ID: 11076108)
1. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients.
Block GA
Clin Nephrol; 2000 Oct; 54(4):318-24. PubMed ID: 11076108
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Review of dialysate calcium concentration in hemodialysis.
Toussaint N; Cooney P; Kerr PG
Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
[TBL] [Abstract][Full Text] [Related]
4. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
5. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
[TBL] [Abstract][Full Text] [Related]
6. Marked improvement in bone metabolism parameters after increasing the dialysate calcium concentration from 2.5 to 3 mEq/L in nonhypercalcemic hemodialysis patients.
Molina Vila P; Sánchez Pérez P; Garrigós Almerich E; Peris Domingo A
Hemodial Int; 2008 Jan; 12(1):73-9. PubMed ID: 18271845
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
9. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
10. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
11. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
[TBL] [Abstract][Full Text] [Related]
12. [Disturbances of mineral metabolism and vascular calcifications in dialysis patients (review)].
Malberti F; Ravani P
G Ital Nefrol; 2004; 21(3):238-44. PubMed ID: 15285002
[TBL] [Abstract][Full Text] [Related]
13. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
Cupisti A; D'Alessandro C; Baldi R; Barsotti G
J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
[TBL] [Abstract][Full Text] [Related]
14. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
[TBL] [Abstract][Full Text] [Related]
15. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
Nolan CR
Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
[TBL] [Abstract][Full Text] [Related]
16. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
[TBL] [Abstract][Full Text] [Related]
17. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
[TBL] [Abstract][Full Text] [Related]
18. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
Block GA; Hulbert-Shearon TE; Levin NW; Port FK
Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
[TBL] [Abstract][Full Text] [Related]
19. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD.
Menon V; Greene T; Pereira AA; Wang X; Beck GJ; Kusek JW; Collins AJ; Levey AS; Sarnak MJ
Am J Kidney Dis; 2005 Sep; 46(3):455-63. PubMed ID: 16129207
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic agents for hyperphosphatemia].
Kurihara S
Clin Calcium; 2002 Oct; 12(10):1435-41. PubMed ID: 15775444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
